Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Saint-Cloud – page 279

3 344 clinical trials in Saint-Cloud, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Saint-Cloud at a glance
3 344
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 344 trials in Saint-Cloud

Open in trial search

Myelofibrosis+1

Not recruiting

Study of Pacritinib for Patients with Severe Thrombocytopenia in Myelofibrosis Conditions

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Sobi Inc.

Primary amyloidosis

Not recruiting

Study on Birtamimab and Bortezomib for Patients with Advanced Light Chain Amyloidosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Birtamimab
  • Sponsor:Prothena Biosciences Limited

Study on Evolocumab for Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Evolocumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Nephropathy

Not recruiting

Study on the Effects of Povetacicept for Adults with IgA Nephropathy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Povetacicept
  • Sponsor:Alpine Immune Sciences Inc.

Study on EYE103 and Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:EYE103
  • Sponsor:Eyebiotech Limited

Study on Durvalumab for Patients with Completely Removed Non-Small Cell Lung Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Clinipace Global Limited

Colitis ulcerative

Not recruiting

Study of RO7790121 Treatment for Adults with Moderate to Severe Ulcerative Colitis: Testing Effectiveness and Safety in Initial and Long-term Therapy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Colitis ulcerative

Not recruiting

Study of RO7790121 Compared to Placebo for Treatment of Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Saint-Cloud

What the registry says about research in the country

01 Blood Cancer Research

Innovative trials focusing on lymphoma and multiple myeloma treatments, including studies of novel therapies like duvelisib for T-cell lymphoma and odronextamab for follicular lymphoma.

  • B-Cell Lymphomas
  • Multiple Myeloma
  • T-Cell Lymphomas

Several studies are evaluating combination therapies and comparing new treatment approaches against standard care.

02 Breast Cancer Studies

Comprehensive research into various types of breast cancer, with particular focus on hormone receptor-positive and triple-negative variants. Studies include early detection methods and novel therapeutic combinations.

  • HR+/HER2- Advanced Breast Cancer
  • Triple-Negative Breast Cancer
  • Early-Stage Disease

Trials incorporate innovative approaches like ctDNA monitoring and targeted therapies.

03 Advanced Cancer Therapies

Research focusing on targeted therapies for various advanced cancers, including studies of biliary tract cancer and non-small cell lung cancer treatments.

  • Lung Cancer
  • Biliary Tract Cancer
  • Prostate Cancer

Emphasis on immunotherapy combinations and precision medicine approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.